Aptamers: Molecules of great potential

Biotechnology Advances

Volumn 31, Issue 8, 2013, Pages 1260-1274

  Radom, Filip ^a   Jurek, Przemysław M ^a   Mazurek, Maciej P ^a   Otlewski, Jacek ^a   Jeleń, Filip ^a  

^a UNIVERSITY OF WROC AW   (Poland)

Author keywords

Aptamer; Aptamers' application; Medical diagnostics; Nanobiotechnology; Oligonucleotide; SELEX; Therapeutic applications

Indexed keywords

APTAMERS; BIOMEDICAL RESEARCH; MEDICAL DIAGNOSTICS; MOLECULAR TARGETS; SELEX; THERAPEUTIC AGENTS; THERAPEUTIC APPLICATION; VERSATILE TOOLS;

NANOBIOTECHNOLOGY; NUCLEIC ACIDS; OLIGONUCLEOTIDES;

MOLECULES;

BIOTECHNOLOGY; MEDICINE; NUCLEIC ACID; RESEARCH;

APTAMER; OLIGONUCLEOTIDE; PEPTIDE APTAMER;

APTAMERS' APPLICATION; BIOTECHNOLOGY; COMBINATORIAL CHEMISTRY; MEDICAL DIAGNOSTICS; NANOBIOTECHNOLOGY; NANOTECHNOLOGY; REVIEW; SELEX; THERAPEUTIC APPLICATIONS;

APTAMER; APTAMERS' APPLICATION; MEDICAL DIAGNOSTICS; NANOBIOTECHNOLOGY; OLIGONUCLEOTIDE; SELEX; THERAPEUTIC APPLICATIONS;

APTAMERS, NUCLEOTIDE; APTAMERS, PEPTIDE; BIOTECHNOLOGY; NANOTECHNOLOGY; SELEX APTAMER TECHNIQUE;

EID: 84887991088     PISSN: 07349750     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biotechadv.2013.04.007     Document Type: Review

References (164)

1. Bates P.J., Laber D.A., Miller D.M., Thomas S.D., Trent J.O. Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Exp Mol Pathol 2009, 86(3):151-164. [Jun].
2. Berezovski M.V., Lechmann M., Musheev M.U., Mak T.W., Krylov S.N. Aptamer-facilitated biomarker discovery (AptaBiD). J Am Chem Soc 2008, 130(28):9137-9143. [Jul 16].
3. Betat H., Vogel S., Struhalla M., Forster H.H., Famulok M., Welzel P., et al. Aptamers that recognize the lipid moiety of the antibiotic moenomycin A. Biol Chem 2003, 384(10-11):1497-1500. [Oct].
4. Blank M., Weinschenk T., Priemer M., Schluesener H. Systematic evolution of a DNA aptamer binding to rat brain tumor microvessels. Selective targeting of endothelial regulatory protein pigpen. J Biol Chem 2001, 276(19):16464-16468. [May 11].
5. Boese B.J., Breaker R.R. In vitro selection and characterization of cellulose-binding DNA aptamers. Nucleic Acids Res 2007, 35(19):6378-6388.
6. Boltz A., Piater B., Toleikis L., Guenther R., Kolmar H., Hock B. Bi-specific aptamers mediating tumor cell lysis. J Biol Chem 2011, 286(24):21896-21905. [Jun 17].
7. Borbas K.E., Ferreira C.S., Perkins A., Bruce J.I., Missailidis S. Design and synthesis of mono- and multimeric targeted radiopharmaceuticals based on novel cyclen ligands coupled to anti-MUC1 aptamers for the diagnostic imaging and targeted radiotherapy of cancer. Bioconjug Chem 2007, 18(4):1205-1212. [Jul].
8. Bunka D.H., Platonova O., Stockley P.G. Development of aptamer therapeutics. Curr Opin Pharmacol 2010, 10(5):557-562. [Oct].
9. Buzdar A.U., Marcus C., Smith T.L., Blumenschein G.R. Early and delayed clinical cardiotoxicity of doxorubicin. Cancer 1985, 55(12):2761-2765. [Jun 15].
10. Chaires J.B., Herrera J.E., Waring M.J. Preferential binding of daunomycin to 5'ATCG and 5'ATGC sequences revealed by footprinting titration experiments. Biochemistry 1990, 29(26):6145-6153. [Jul 3].
11. Charlton J., Kirschenheuter G.P., Smith D. Highly potent irreversible inhibitors of neutrophil elastase generated by selection from a randomized DNA-valine phosphonate library. Biochemistry 1997, 36(10):3018-3026. [Mar 11a].
12. Charlton J., Sennello J., Smith D. In vivo imaging of inflammation using an aptamer inhibitor of human neutrophil elastase. Chem Biol 1997, 4(11):809-816. [Novb].
13. Chen H.W., Medley C.D., Sefah K., Shangguan D., Tang Z., Meng L., et al. Molecular recognition of small-cell lung cancer cells using aptamers. ChemMedChem 2008, 3(6):991-1001. [Jun].
14. Chen F., Hu Y., Li D., Chen H., Zhang X.L. CS-SELEX generates high-affinity ssDNA aptamers as molecular probes for hepatitis C virus envelope glycoprotein E2. PLoS One 2009, 4(12):e8142.
15. Cheng J., Teply B.A., Sherifi I., Sung J., Luther G., Gu F.X., et al. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials 2007, 28(5):869-876. [Feb].
16. Ciesiolka J., Gorski J., Yarus M. Selection of an RNA domain that binds Zn2+. RNA 1995, 1(5):538-550. [Jul].
17. Collett J.R., Cho E.J., Ellington A.D. Production and processing of aptamer microarrays. Methods 2005, 37(1):4-15. [Sepa].
18. Collett J.R., Cho E.J., Lee J.F., Levy M., Hood A.J., Wan C., et al. Functional RNA microarrays for high-throughput screening of antiprotein aptamers. Anal Biochem 2005, 338(1):113-123. [Mar 1b].
19. Connor A.C., McGown L.B. Aptamer stationary phase for protein capture in affinity capillary chromatography. J Chromatogr A 2006, 1111(2):115-119. [Apr 14].
20. Cummins L.L., Owens S.R., Risen L.M., Lesnik E.A., Freier S.M., McGee D., et al. Characterization of fully 2'-modified oligoribonucleotide hetero- and homoduplex hybridization and nuclease sensitivity. Nucleic Acids Res 1995, 23(11):2019-2024. [Jun 11].
21. Da Rocha G.S., Miguel J., Azema L., Eimer S., Ries C., Dausse E., et al. (99m)Tc-MAG3-aptamer for imaging human tumors associated with high level of matrix metalloprotease-9. Bioconjug Chem 2012, 23(11):2192-2200. [Nov 21].
22. Davies D. Cell separations by flow cytometry. Methods Mol Biol 2012, 878:185-199.
23. Deng Q., German I., Buchanan D., Kennedy R.T. Retention and separation of adenosine and analogues by affinity chromatography with an aptamer stationary phase. Anal Chem 2001, 73(22):5415-5421. [Nov 15].
24. Dhar S., Kolishetti N., Lippard S.J., Farokhzad O.C. Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo. Proc Natl Acad Sci U S A 2011, 108(5):1850-1855. [Feb 1].
25. Ding K., Alemdaroglu F.E., Borsch M., Berger R., Herrmann A. Engineering the structural properties of DNA block copolymer micelles by molecular recognition. Angew Chem Int Ed Engl 2007, 46(7):1172-1175.
26. Dollins C.M., Nair S., Boczkowski D., Lee J., Layzer J.M., Gilboa E., et al. Assembling OX40 aptamers on a molecular scaffold to create a receptor-activating aptamer. Chem Biol 2008, 15(7):675-682. [Jul 21].
27. Doubrovin M., Serganova I., Mayer-Kuckuk P., Ponomarev V., Blasberg R.G. Multimodality in vivo molecular-genetic imaging. Bioconjug Chem 2004, 15(6):1376-1388. [Nov].
28. Douglas S.M., Marblestone A.H., Teerapittayanon S., Vazquez A., Church G.M., Shih W.M. Rapid prototyping of 3D DNA-origami shapes with caDNAno. Nucleic Acids Res 2009, 37(15):5001-5006. [Aug].
29. Douglas S.M., Bachelet I., Church G.M. A logic-gated nanorobot for targeted transport of molecular payloads. Science 2012, 335(6070):831-834. [Feb 17].
30. Duboisset J., Russier-Antoine I., Benichou E., Bachelier G., Jonin C., Brevet P.F. Single metallic nanoparticle sensitivity with hyper Rayleigh scattering. J Phys Chem C 2009, 113(31):13477-13481. [Jul 8].
31. Dunham I., Kundaje A., Aldred S.F., Collins P.J., Davis C.A., Doyle F., et al. An integrated encyclopedia of DNA elements in the human genome. Nature 2012, 489(7414):57-74. [Sep 6].
32. Dwivedi H.P., Smiley R.D., Jaykus L.A. Selection and characterization of DNA aptamers with binding selectivity to Campylobacter jejuni using whole-cell SELEX. Appl Microbiol Biotechnol 2010, 87(6):2323-2334. [Aug].
33. Elbaz J., Shlyahovsky B., Li D., Willner I. Parallel analysis of two analytes in solutions or on surfaces by using a bifunctional aptamer: applications for biosensing and logic gate operations. Chembiochem 2008, 9(2):232-239. [Jan 25].
34. Engin K. Biological rationale for hyperthermia in cancer treatment (II). Neoplasma 1994, 41(5):277-283.
35. Esposito C.L., Catuogno S., de F V., Cerchia L. New insight into clinical development of nucleic acid aptamers. Discov Med 2011, 11(61):487-496. [Jun].
36. Fan P., Suri A.K., Fiala R., Live D., Patel D.J. Molecular recognition in the FMN-RNA aptamer complex. J Mol Biol 1996, 258(3):480-500. [May 10].
37. Fang X., Sen A., Vicens M., Tan W. Synthetic DNA aptamers to detect protein molecular variants in a high-throughput fluorescence quenching assay. Chembiochem 2003, 4(9):829-834. [Sep 5].
38. Farokhzad O.C., Jon S., Khademhosseini A., Tran T.N., Lavan D.A., Langer R. Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res 2004, 64(21):7668-7672. [Nov 1].
39. Flint M., McKeating J.A. The role of the hepatitis C virus glycoproteins in infection. Rev Med Virol 2000, 10(2):101-117. [Mar].
40. Fossati G., Bucknall R.C., Edwards S.W. Fcgamma receptors in autoimmune diseases. Eur J Clin Invest 2001, 31(9):821-831. [Sep].
41. Gendler S.J. MUC1, the renaissance molecule. J Mammary Gland Biol Neoplasia 2001, 6(3):339-353. [Jul].
42. Gerstein M.B., Kundaje A., Hariharan M., Landt S.G., Yan K.K., Cheng C., et al. Architecture of the human regulatory network derived from ENCODE data. Nature 2012, 489(7414):91-100. [Sep 6].
43. Girardot M., Gareil P., Varenne A. Interaction study of a lysozyme-binding aptamer with mono- and divalent cations by ACE. Electrophoresis 2010, 31(3):546-555. [Jan].
44. Gold L., Janjic N., Jarvis T., Schneider D., Walker J.J., Wilcox S.K., et al. Aptamers and the RNA world, past and present. Cold Spring Harb Perspect Biol 2012, 4(3). [Mara].
45. Gold L., Walker J.J., Wilcox S.K., Williams S. Advances in human proteomics at high scale with the SOMAscan proteomics platform. N Biotechnol 2012, 29(5):543-549. [Jun 15b].
46. Green L.S., Jellinek D., Jenison R., Ostman A., Heldin C.H., Janjic N. Inhibitory DNA ligands to platelet-derived growth factor B-chain. Biochemistry 1996, 35(45):14413-14424. [Nov 12].
47. Guo Y.P., Guo L.H., Yao Y.B., Ning C.Q., Guo Y.J. Magnetic mesoporous carbonated hydroxyapatite microspheres with hierarchical nanostructure for drug delivery systems. Chem Commun (Camb) 2011, 47(44):12215-12217. [Nov 28].
48. Hamaguchi N., Ellington A., Stanton M. Aptamer beacons for the direct detection of proteins. Anal Biochem 2001, 294(2):126-131. [Jul 15].
49. He J.L., Wu Z.S., Zhang S.B., Shen G.L., Yu R.Q. Fluorescence aptasensor based on competitive-binding for human neutrophil elastase detection. Talanta 2010, 80(3):1264-1268. [Jan 15].
50. Hicke B.J., Marion C., Chang Y.F., Gould T., Lynott C.K., Parma D., et al. Tenascin-C aptamers are generated using tumor cells and purified protein. J Biol Chem 2001, 276(52):48644-48654. [Dec 28].
51. Hicke B.J., Stephens A.W., Gould T., Chang Y.F., Lynott C.K., Heil J., et al. Tumor targeting by an aptamer. J Nucl Med 2006, 47(4):668-678. [Apr].
52. Hofmann H.P., Limmer S., Hornung V., Sprinzl M. Ni2+-binding RNA motifs with an asymmetric purine-rich internal loop and a G-A base pair. RNA 1997, 3(11):1289-1300. [Nov].
53. Homann M., Goringer H.U. Combinatorial selection of high affinity RNA ligands to live African trypanosomes. Nucleic Acids Res 1999, 27(9):2006-2014. [May 1].
54. Huang Y.F., Sefah K., Bamrungsap S., Chang H.T., Tan W. Selective photothermal therapy for mixed cancer cells using aptamer-conjugated nanorods. Langmuir 2008, 24(20):11860-11865. [Oct 21].
55. Huang Y.F., Shangguan D., Liu H., Phillips J.A., Zhang X., Chen Y., et al. Molecular assembly of an aptamer-drug conjugate for targeted drug delivery to tumor cells. Chembiochem 2009, 10(5):862-868. [Mar 23].
56. Huff T.B., Tong L., Zhao Y., Hansen M.N., Cheng J.X., Wei A. Hyperthermic effects of gold nanorods on tumor cells. Nanomedicine (Lond) 2007, 2(1):125-132. [Feb].
57. Huizenga D.E., Szostak J.W. A DNA aptamer that binds adenosine and ATP. Biochemistry 1995, 34(2):656-665. [Jan 17].
58. Hwang dW, Ko H.Y., Lee J.H., Kang H., Ryu S.H., Song I.C., et al. A nucleolin-targeted multimodal nanoparticle imaging probe for tracking cancer cells using an aptamer. J Nucl Med 2010, 51(1):98-105. [Jan].
59. Irvine D., Tuerk C., Gold L. SELEXION. Systematic evolution of ligands by exponential enrichment with integrated optimization by non-linear analysis. J Mol Biol 1991, 222(3):739-761. [Dec 5].
60. Israeli R.S., Powell C.T., Corr J.G., Fair W.R., Heston W.D. Expression of the prostate-specific membrane antigen. Cancer Res 1994, 54(7):1807-1811. [Apr 1].
61. Ito T., Ueno Y., Komatsu Y., Matsuda A. Synthesis, thermal stability and resistance to enzymatic hydrolysis of the oligonucleotides containing 5-(N-aminohexyl)carbamoyl-2'-O-methyluridines. Nucleic Acids Res 2003, 31(10):2514-2523. [May 15].
62. Iwagawa T., Ohuchi S.P., Watanabe S., Nakamura Y. Selection of RNA aptamers against mouse embryonic stem cells. Biochimie 2012, 94(1):250-257. [Jan].
63. Jeong S., Eom T., Kim S., Lee S., Yu J. In vitro selection of the RNA aptamer against the Sialyl Lewis X and its inhibition of the cell adhesion. Biochem Biophys Res Commun 2001, 281(1):237-243. [Feb 16].
64. Kang H., O'Donoghue M.B., Liu H., Tan W. A liposome-based nanostructure for aptamer directed delivery. Chem Commun (Camb) 2010, 46(2):249-251. [Jan 14].
65. Kennedy M.K., Willis C.R., Armitage R.J. Deciphering CD30 ligand biology and its role in humoral immunity. Immunology 2006, 118(2):143-152. [Jun].
66. Khan S.A., Kanchanapally R., Fan Z., Beqa L., Singh A.K., Senapati D., et al. A gold nanocage-CNT hybrid for targeted imaging and photothermal destruction of cancer cells. Chem Commun (Camb) 2012, 48(53):6711-6713. [Jul 7].
67. Kim Y.S., Hyun C.J., Kim I.A., Gu M.B. Isolation and characterization of enantioselective DNA aptamers for ibuprofen. Bioorg Med Chem 2010, 18(10):3467-3473. [May 15].
68. Kim Y.S., Song M.Y., Jurng J., Kim B.C. Isolation and characterization of DNA aptamers against Escherichia coli using a bacterial cell-systematic evolution of ligands by exponential enrichment approach. Anal Biochem 2013, 436(1):22-28. [Jan 26].
69. King S., Huh Y., Kim S., Lee D.-K. Isolation of RNA aptamers targeting HER-2-overexpressing breast cancer cells using cell-SELEX. Bull Korean Chem Soc 2009, 30:1827-1831. [Ref Type: Generic].
70. Kirby R., Cho E.J., Gehrke B., Bayer T., Park Y.S., Neikirk D.P., et al. Aptamer-based sensor arrays for the detection and quantitation of proteins. Anal Chem 2004, 76(14):4066-4075. [Jul 15].
71. Klussmann S., Nolte A., Bald R., Erdmann V.A., Furste J.P. Mirror-image RNA that binds d-adenosine. Nat Biotechnol 1996, 14(9):1112-1115. [Sep].
72. Kokpinar O., Walter J.G., Shoham Y., Stahl F., Scheper T. Aptamer-based downstream processing of his-tagged proteins utilizing magnetic beads. Biotechnol Bioeng 2011, 108(10):2371-2379. [Oct 1].
73. Kusser W. Chemically modified nucleic acid aptamers for in vitro selections: evolving evolution. J Biotechnol 2000, 74(1):27-38. [Mar].
74. Lai Y.T., Destefano J.J. A primer-free method that selects high-affinity single-stranded DNA aptamers using thermostable RNA ligase. Anal Biochem 2011, 414(2):246-253. [Jul 15].
75. Lai Y.T., Destefano J.J. DNA aptamers to human immunodeficiency virus reverse transcriptase selected by a primer-free SELEX method: characterization and comparison with other aptamers. Nucleic Acid Ther 2012, 22(3):162-176. [Jun].
76. Lee Y.J., Han S.R., Maeng J.S., Cho Y.J., Lee S.W. In vitro selection of Escherichia coli O157:H7-specific RNA aptamer. Biochem Biophys Res Commun 2012, 417(1):414-420. [Jan 6].
77. Levine H.A., Nilsen-Hamilton M. A mathematical analysis of SELEX. Comput Biol Chem 2007, 31(1):11-35. [Feb].
78. Li W., Yang X., Wang K., Tan W., Li H., Ma C. FRET-based aptamer probe for rapid angiogenin detection. Talanta 2008, 75(3):770-774. [May 15].
79. Li Z., Liu Z., Yin M., Yang X., Yuan Q., Ren J., et al. Aptamer-capped multifunctional mesoporous strontium hydroxyapatite nanovehicle for cancer-cell-responsive drug delivery and imaging. Biomacromolecules 2012, 13(12):4257-4263. [Dec 10].
80. Lin Y., Qiu Q., Gill S.C., Jayasena S.D. Modified RNA sequence pools for in vitro selection. Nucleic Acids Res 1994, 22(24):5229-5234. [Dec 11].
81. Lin Y., Padmapriya A., Morden K.M., Jayasena S.D. Peptide conjugation to an in vitro-selected DNA ligand improves enzyme inhibition. Proc Natl Acad Sci U S A 1995, 92(24):11044-11048. [Nov 21].
82. Lin Z., Chen L., Zhang G., Liu Q., Qiu B., Cai Z., et al. Label-free aptamer-based electrochemical impedance biosensor for 17[small beta]-estradiol. Analyst 2012, 137(4):819-822.
83. Liu G., Mao X., Phillips J.A., Xu H., Tan W., Zeng L. Aptamer-nanoparticle strip biosensor for sensitive detection of cancer cells. Anal Chem 2009, 81(24):10013-10018. [Dec 15].
84. Lorsch J.R., Szostak J.W. In vitro selection of RNA aptamers specific for cyanocobalamin. Biochemistry 1994, 33(4):973-982. [Feb 1].
85. Lu W., Arumugam S.R., Senapati D., Singh A.K., Arbneshi T., Khan S.A., et al. Multifunctional oval-shaped gold-nanoparticle-based selective detection of breast cancer cells using simple colorimetric and highly sensitive two-photon scattering assay. ACS Nano 2010, 4(3):1739-1749. [Mar 23].
86. Lupold S.E., Hicke B.J., Lin Y., Coffey D.S. Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res 2002, 62(14):4029-4033. [Jul 15].
87. Macaya R.F., Schultze P., Smith F.W., Roe J.A., Feigon J. Thrombin-binding DNA aptamer forms a unimolecular quadruplex structure in solution. Proc Natl Acad Sci U S A 1993, 90(8):3745-3749. [Apr 15].
88. Macbeath G. Protein microarrays and proteomics. Nat Genet 2002, 32:526-532. [Dec, Suppl].
89. Mandal M., Breaker R.R. Gene regulation by riboswitches. Nat Rev Mol Cell Biol 2004, 5(6):451-463. [Jun].
90. Mann A.P., Bhavane R.C., Somasunderam A., Liz Montalvo-Ortiz B., Ghaghada K.B., Volk D., et al. Thioaptamer conjugated liposomes for tumor vasculature targeting. Oncotarget 2011, 2(4):298-304. [Apr].
91. Marimuthu C., Tang T.H., Tominaga J., Tan S.C., Gopinath S.C. Single-stranded DNA (ssDNA) production in DNA aptamer generation. Analyst 2012, 137(6):1307-1315. [Mar 21].
92. McNamara J.O., Kolonias D., Pastor F., Mittler R.S., Chen L., Giangrande P.H., et al. Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice. J Clin Invest 2008, 118(1):376-386. [Jan].
93. Mikhail A.S., Allen C. Block copolymer micelles for delivery of cancer therapy: transport at the whole body, tissue and cellular levels. J Control Release 2009, 138(3):214-223. [Sep 15].
94. Mitchell P. Proteomics retrenches. Nat Biotechnol 2010, 28(7):665-670. [Jul].
95. Miyachi Y., Shimizu N., Ogino C., Fukuda H., Kondo A. Selection of a DNA aptamer that binds 8-OHdG using GMP-agarose. Bioorg Med Chem Lett 2009, 19(13):3619-3622. [Jul 1].
96. Morris K.N., Jensen K.B., Julin C.M., Weil M., Gold L. High affinity ligands from in vitro selection: complex targets. Proc Natl Acad Sci U S A 1998, 95(6):2902-2907. [Mar 17].
97. Mosing R.K., Mendonsa S.D., Bowser M.T. Capillary electrophoresis-SELEX selection of aptamers with affinity for HIV-1 reverse transcriptase. Anal Chem 2005, 77(19):6107-6112. [Oct 1].
98. Murphy M.B., Fuller S.T., Richardson P.M., Doyle S.A. An improved method for the in vitro evolution of aptamers and applications in protein detection and purification. Nucleic Acids Res 2003, 31(18):e110. [Sep 15].
99. Nagatoishi S., Nojima T., Galezowska E., Gluszynska A., Juskowiak B., Takenaka S. Fluorescence energy transfer probes based on the guanine quadruplex formation for the fluorometric detection of potassium ion. Anal Chim Acta 2007, 581(1):125-131. [Jan 2].
100. Ng E.W., Shima D.T., Calias P., Cunningham E.T., Guyer D.R., Adamis A.P. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 2006, 5(2):123-132. [Feb].
101. Ni X., Zhang Y., Ribas J., Chowdhury W.H., Castanares M., Zhang Z., et al. Prostate-targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts. J Clin Invest 2011, 121(6):2383-2390. [Jun].
102. Oh S.S., Ahmad K.M., Cho M., Kim S., Xiao Y., Soh H.T. Improving aptamer selection efficiency through volume dilution, magnetic concentration, and continuous washing in microfluidic channels. Anal Chem 2011, 83(17):6883-6889. [Sep 1].
103. Orend G. Potential oncogenic action of tenascin-C in tumorigenesis. Int J Biochem Cell Biol 2005, 37(5):1066-1083. [May].
104. Ostroff R.M., Bigbee W.L., Franklin W., Gold L., Mehan M., Miller Y.E., et al. Unlocking biomarker discovery: large scale application of aptamer proteomic technology for early detection of lung cancer. PLoS One 2010, 5(12):e15003.
105. Padmanabhan K., Padmanabhan K.P., Ferrara J.D., Sadler J.E., Tulinsky A. The structure of alpha-thrombin inhibited by a 15-mer single-stranded DNA aptamer. J Biol Chem 1993, 268(24):17651-17654. [Aug 25].
106. Pan W., Xin P., Clawson G.A. Minimal primer and primer-free SELEX protocols for selection of aptamers from random DNA libraries. Biotechniques 2008, 44(3):351-360. [Mar].
107. Pan W., Xin P., Patrick S., Dean S., Keating C., Clawson G. Primer-free aptamer selection using a random DNA library. J Vis Exp 2010, (41).
108. Perkins A.C., Missailidis S. Radiolabelled aptamers for tumour imaging and therapy. Q J Nucl Med Mol Imaging 2007, 51(4):292-296. [Dec].
109. Pieve C.D., Perkins A.C., Missailidis S. Anti-MUC1 aptamers: radiolabelling with (99m)Tc and biodistribution in MCF-7 tumour-bearing mice. Nucl Med Biol 2009, 36(6):703-710. [Aug].
110. Pissuwan D., Valenzuela S.M., Miller C.M., Cortie M.B. A golden bullet? Selective targeting of Toxoplasma gondii tachyzoites using antibody-functionalized gold nanorods. Nano Lett 2007, 7(12):3808-3812. [Dec].
111. Purschke W.G., Radtke F., Kleinjung F., Klussmann S. A DNA Spiegelmer to staphylococcal enterotoxin B. Nucleic Acids Res 2003, 31(12):3027-3032. [Jun 15].
112. Radi A.E., Acero Sanchez J.L., Baldrich E., O'Sullivan C.K. Reusable impedimetric aptasensor. Anal Chem 2005, 77(19):6320-6323. [Oct 1].
113. Ravelet C., Grosset C., Peyrin E. Liquid chromatography, electrochromatography and capillary electrophoresis applications of DNA and RNA aptamers. J Chromatogr A 2006, 1117(1):1-10. [Jun 2].
114. Rockey W.M., Huang L., Kloepping K.C., Baumhover N.J., Giangrande P.H., Schultz M.K. Synthesis and radiolabeling of chelator-RNA aptamer bioconjugates with copper-64 for targeted molecular imaging. Bioorg Med Chem 2011, 19(13):4080-4090. [Jul 1].
115. Rodriguez M.C., Kawde A.N., Wang J. Aptamer biosensor for label-free impedance spectroscopy detection of proteins based on recognition-induced switching of the surface charge. Chem Commun (Camb) 2005, (34):4267-4269. [Sep 14].
116. Romig T.S., Bell C., Drolet D.W. Aptamer affinity chromatography: combinatorial chemistry applied to protein purification. J Chromatogr B Biomed Sci Appl 1999, 731(2):275-284. [Aug 20].
117. Rong S., Donehower L.A., Hansen M.F., Strong L., Tainsky M., Jeffers M., et al. Met proto-oncogene product is overexpressed in tumors of p53-deficient mice and tumors of Li-Fraumeni patients. Cancer Res 1995, 55(9):1963-1970. [May 1].
118. Ruckman J., Green L.S., Beeson J., Waugh S., Gillette W.L., Henninger D.D., et al. 2'-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J Biol Chem 1998, 273(32):20556-20567. [Aug 7].
119. Rusconi C.P., Scardino E., Layzer J., Pitoc G.A., Ortel T.L., Monroe D., et al. RNA aptamers as reversible antagonists of coagulation factor IXa. Nature 2002, 419(6902):90-94. [Sep 5].
120. Sampson T. Aptamers and SELEX: the technology. World Patent Inf 2003, 25(2):123-129. [Jun].
121. Savory N., Abe K., Sode K., Ikebukuro K. Selection of DNA aptamer against prostate specific antigen using a genetic algorithm and application to sensing. Biosens Bioelectron 2010, 26(4):1386-1391. [Dec 15].
122. Sayyed S.G., Hagele H., Kulkarni O.P., Endlich K., Segerer S., Eulberg D., et al. Podocytes produce homeostatic chemokine stromal cell-derived factor-1/CXCL12, which contributes to glomerulosclerosis, podocyte loss and albuminuria in a mouse model of type 2 diabetes. Diabetologia 2009, 52(11):2445-2454. [Nov].
123. Schultze P., Macaya R.F., Feigon J. Three-dimensional solution structure of the thrombin-binding DNA aptamer d(GGTTGGTGTGGTTGG). J Mol Biol 1994, 235(5):1532-1547. [Feb 4].
124. Sefah K., Tang Z.W., Shangguan D.H., Chen H., Lopez-Colon D., Li Y., et al. Molecular recognition of acute myeloid leukemia using aptamers. Leukemia 2009, 23(2):235-244. [Feb].
125. Shangguan D., Li Y., Tang Z., Cao Z.C., Chen H.W., Mallikaratchy P., et al. Aptamers evolved from live cells as effective molecular probes for cancer study. Proc Natl Acad Sci U S A 2006, 103(32):11838-11843. [Aug 8].
126. Shin S., Kim I.H., Kang W., Yang J.K., Hah S.S. An alternative to Western blot analysis using RNA aptamer-functionalized quantum dots. Bioorg Med Chem Lett 2010, 20(11):3322-3325. [Jun 1].
127. Shtatland T., Gill S.C., Javornik B.E., Johansson H.E., Singer B.S., Uhlenbeck O.C., et al. Interactions of Escherichia coli RNA with bacteriophage MS2 coat protein: genomic SELEX. Nucleic Acids Res 2000, 28(21):E93. [Nov 1].
128. Sledge G.W., Neuberg D., Bernardo P., Ingle J.N., Martino S., Rowinsky E.K., et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 2003, 21(4):588-592. [Feb 15].
129. Smith J.E., Medley C.D., Tang Z., Shangguan D., Lofton C., Tan W. Aptamer-conjugated nanoparticles for the collection and detection of multiple cancer cells. Anal Chem 2007, 79(8):3075-3082. [Apr 15].
130. Sook Bang G., Cho S., Lee N., Lee B.R., Kim J.H., Kim B.G. Rational design of modular allosteric aptamer sensor for label-free protein detection. Biosens Bioelectron 2013, 39(1):44-50. [Jan 15].
131. Stamenkovic I. Extracellular matrix remodelling: the role of matrix metalloproteinases. J Pathol 2003, 200(4):448-464. [Jul].
132. Stevenson R., Baxter H.C., Aitken A., Brown T., Baxter R.L. Binding of 14-3-3 proteins to a single stranded oligodeoxynucleotide aptamer. Bioorg Chem 2008, 36(5):215-219. [Oct].
133. Stoltenburg R., Reinemann C., Strehlitz B. SELEX - a (r)evolutionary method to generate high-affinity nucleic acid ligands. Biomol Eng 2007, 24(4):381-403. [Oct].
134. Sundaram P., Kurniawan H., Byrne M.E., Wower J. Therapeutic RNA aptamers in clinical trials. Eur J Pharm Sci 2013, 48(1-2):259-271. [Jan 23].
135. Svobodova M., Pinto A., Nadal P., O' Sullivan C.K. Comparison of different methods for generation of single-stranded DNA for SELEX processes. Anal Bioanal Chem 2012, 404(3):835-842. [Aug].
136. Swensen J.S., Xiao Y., Ferguson B.S., Lubin A.A., Lai R.Y., Heeger A.J., et al. Continuous, real-time monitoring of cocaine in undiluted blood serum via a microfluidic, electrochemical aptamer-based sensor. J Am Chem Soc 2009, 131(12):4262-4266. [Apr 1].
137. Tanaka Y., Honda T., Matsuura K., Kimura Y., Inui M. In vitro selection and characterization of DNA aptamers specific for phospholamban. J Pharmacol Exp Ther 2009, 329(1):57-63. [Apr].
138. Tang Z., Parekh P., Turner P., Moyer R.W., Tan W. Generating aptamers for recognition of virus-infected cells. Clin Chem 2009, 55(4):813-822. [Apr].
139. Terazono H., Anzai Y., Soloviev M., Yasuda K. Labelling of live cells using fluorescent aptamers: binding reversal with DNA nucleases. J Nanobiotechnol 2010, 8:8.
140. Thiviyanathan V., Somasunderam A.D., Gorenstein D.G. Combinatorial selection and delivery of thioaptamers. Biochem Soc Trans 2007, 35(Pt 1):50-52. [Feb].
141. Toscano-Garibay J.D., Benitez-Hess M.L., Alvarez-Salas L.M. Isolation and characterization of an RNA aptamer for the HPV-16 E7 oncoprotein. Arch Med Res 2011, 42(2):88-96. [Feb].
142. Travascio P., Li Y., Sen D. DNA-enhanced peroxidase activity of a DNA-aptamer-hemin complex. Chem Biol 1998, 5(9):505-517. [Sep].
143. Tucker B.J., Breaker R.R. Riboswitches as versatile gene control elements. Curr Opin Struct Biol 2005, 15(3):342-348. [Jun].
144. Tuerk C., Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990, 249(4968):505-510. [Aug 3].
145. Ueno Y., Mikawa M., Matsuda A. Nucleosides and nucleotides. 170. Synthesis and properties of oligodeoxynucleotides containing 5-[N-[2-[N, N-bis(2-aminoethyl)-amino]ethyl]carbamoyl]-2'-deoxyuridine and 5-[N-[3-[N, N-bis(3-aminopropyl) amino]propyl]carbamoyl]-2'-deoxyuridine. Bioconjug Chem 1998, 9(1):33-39. [Jan].
146. Ulrich H., Magdesian M.H., Alves M.J., Colli W. In vitro selection of RNA aptamers that bind to cell adhesion receptors of Trypanosoma cruzi and inhibit cell invasion. J Biol Chem 2002, 277(23):20756-20762. [Jun 7].
147. Umehara T., Fukuda K., Nishikawa F., Kohara M., Hasegawa T., Nishikawa S. Rational design of dual-functional aptamers that inhibit the protease and helicase activities of HCV NS3. J Biochem 2005, 137(3):339-347. [Mar].
148. Van Dort M.E., Rehemtulla A., Ross B.D. PET and SPECT imaging of tumor biology: new approaches towards oncology drug discovery and development. Curr Comput Aided Drug Des 2008, 4(1):46-53.
149. Vater A., Jarosch F., Buchner K., Klussmann S. Short bioactive Spiegelmers to migraine-associated calcitonin gene-related peptide rapidly identified by a novel approach: tailored-SELEX. Nucleic Acids Res 2003, 31(21):e130. [Nov 1].
150. Vuyisich M., Beal P.A. Controlling protein activity with ligand-regulated RNA aptamers. Chem Biol 2002, 9(8):907-913. [Aug].
151. Wang A.Z., Bagalkot V., Vasilliou C.C., Gu F., Alexis F., Zhang L., et al. Superparamagnetic iron oxide nanoparticle-aptamer bioconjugates for combined prostate cancer imaging and therapy. ChemMedChem 2008, 3(9):1311-1315. [Sep].
152. Waters E.K., Genga R.M., Schwartz M.C., Nelson J.A., Schaub R.G., Olson K.A., et al. Aptamer ARC19499 mediates a procoagulant hemostatic effect by inhibiting tissue factor pathway inhibitor. Blood 2011, 117(20):5514-5522. [May 19].
153. Waybrant B., Pearce T.R., Wang P., Sreevatsan S., Kokkoli E. Development and characterization of an aptamer binding ligand of fractalkine using domain targeted SELEX. Chem Commun (Camb) 2012, 48(80):10043-10045. [Oct 14].
154. Weiss R.B., Sarosy G., Clagett-Carr K., Russo M., Leyland-Jones B. Anthracycline analogs: the past, present, and future. Cancer Chemother Pharmacol 1986, 18(3):185-197.
155. Wheeler L.A., Trifonova R., Vrbanac V., Basar E., McKernan S., Xu Z., et al. Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimeras. J Clin Invest 2011, 121(6):2401-2412. [Jun].
156. White R., Rusconi C., Scardino E., Wolberg A., Lawson J., Hoffman M., et al. Generation of species cross-reactive aptamers using "toggle" SELEX. Mol Ther 2001, 4(6):567-573. [Dec].
157. Wu Y., Sefah K., Liu H., Wang R., Tan W. DNA aptamer-micelle as an efficient detection/delivery vehicle toward cancer cells. Proc Natl Acad Sci U S A 2010, 107(1):5-10. [Jan 5].
158. Zhang P., Zhao N., Zeng Z., Feng Y., Tung C.H., Chang C.C., et al. Using an RNA aptamer probe for flow cytometry detection of CD30-expressing lymphoma cells. Lab Invest 2009, 89(12):1423-1432. [Dec].
159. Zhang J., Wang L., Zhang H., Boey F., Song S., Fan C. Aptamer-based multicolor fluorescent gold nanoprobes for multiplex detection in homogeneous solution. Small 2010, 6(2):201-204. [Jan].
160. Zhang H., Jiang B., Xiang Y., Chai Y., Yuan R. Label-free and amplified electrochemical detection of cytokine based on hairpin aptamer and catalytic DNAzyme. Analyst 2012, 137(4):1020-1023. [Feb 21].
161. Zhou J., Rossi J.J. Aptamer-targeted cell-specific RNA interference. Silence 2010, 1(1):4.
162. Zhou J., Li H., Li S., Zaia J., Rossi J.J. Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy. Mol Ther 2008, 16(8):1481-1489. [Aug].
163. Zhou J., Neff C.P., Swiderski P., Li H., Smith D.D., Aboellail T., et al. Functional in vivo delivery of multiplexed anti-HIV-1 siRNAs via a chemically synthesized aptamer with a sticky bridge. Mol Ther 2013, 21(1):192-200. [Jan].
164. Zhu Q., Shibata T., Kabashima T., Kai M. Inhibition of HIV-1 protease expression in T cells owing to DNA aptamer-mediated specific delivery of siRNA. Eur J Med Chem 2012, 56:396-399. [Oct].